Literature DB >> 29617527

Association of Hidradenitis Suppurativa With T Helper 1/T Helper 17 Phenotypes: A Semantic Map Analysis.

Rahel Thomi1, Simone Cazzaniga1,2,3, S Morteza Seyed Jafari1, Christoph Schlapbach1, Robert E Hunger1.   

Abstract

Importance: In spite of progress in understanding the mechanisms underlying hidradenitis suppurativa (HS) as an inflammatory skin disease, there is still a demand for an overview on immunopathogenesis of HS. Objective: To demonstrate the importance of the type 1/type 17 immune response in lesional HS skin by drawing a semantic connectivity map. Design, Setting, and Participants: Single-center case series of 24 patients with HS. Association of HS with T helper 1/T helper 17 (TH1/TH17) phenotype was assessed using semantic map analysis. Main Outcomes and Measures: Association of HS with TH1/TH17 phenotype.
Results: The analysis was performed on 24 lesional HS biopsy samples from untreated patients with HS (16 [67%] female; median age, 36.5 years [range, 21-51 years]) with a mean (SD) Hurley stage of 2.29 (0.62) and 9 punch biopsy samples from healthy controls (6 [67%] female; median age, 43 years [range, 23-66 years]). The map shows a clustering of all TH1/TH17-associated cytokines (interleukin 17 [IL-17], interferon γ, IL-12, IL-23, IL-32, IL-1β, tumor necrosis factor) around overall lesional inflammation. Tumor necrosis factor, IL-12, and IL-17 are even directly connected via interferon γ. In contrast, IL-13, a TH2-associated cytokine, was inversely correlated with the presence of TH1/TH17-associated cytokines, further highlighting the importance of the TH1/TH17 cytokines in HS pathogenesis. Conclusions and Relevance: These findings suggest that HS may be a TH1/TH17-driven inflammatory skin disease.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29617527      PMCID: PMC6128497          DOI: 10.1001/jamadermatol.2018.0141

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  14 in total

Review 1.  Clinical practice. Hidradenitis suppurativa.

Authors:  Gregor B E Jemec
Journal:  N Engl J Med       Date:  2012-01-12       Impact factor: 91.245

2.  Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

Authors:  Christopher E M Griffiths; Bruce E Strober; Peter van de Kerkhof; Vincent Ho; Roseanne Fidelus-Gort; Newman Yeilding; Cynthia Guzzo; Yichuan Xia; Bei Zhou; Shu Li; Lisa T Dooley; Neil H Goldstein; Alan Menter
Journal:  N Engl J Med       Date:  2010-01-14       Impact factor: 91.245

3.  Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases.

Authors:  Carine Houriet; S Morteza Seyed Jafari; Rahel Thomi; Christoph Schlapbach; Luca Borradori; Nikhil Yawalkar; Robert E Hunger
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

4.  Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa.

Authors:  Christoph Schlapbach; Tanja Hänni; Nikhil Yawalkar; Robert E Hunger
Journal:  J Am Acad Dermatol       Date:  2011-10       Impact factor: 11.527

5.  Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions.

Authors:  H H van der Zee; L de Ruiter; J Boer; D G van den Broecke; J C den Hollander; J D Laman; E P Prens
Journal:  Br J Dermatol       Date:  2011-12-05       Impact factor: 9.302

6.  Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa.

Authors:  S Kamp; A M Fiehn; K Stenderup; C Rosada; B Pakkenberg; K Kemp; T N Dam; G B Jemec
Journal:  Br J Dermatol       Date:  2011-05       Impact factor: 9.302

7.  Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa.

Authors:  Kerstin Wolk; Katarzyna Warszawska; Conny Hoeflich; Ellen Witte; Sylke Schneider-Burrus; Katrin Witte; Stefanie Kunz; Annette Buss; Hans Joachim Roewert; Markus Krause; Ansgar Lukowsky; Hans-Dieter Volk; Wolfram Sterry; Robert Sabat
Journal:  J Immunol       Date:  2010-12-08       Impact factor: 5.422

8.  Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.

Authors:  H H van der Zee; L de Ruiter; D G van den Broecke; W A Dik; J D Laman; E P Prens
Journal:  Br J Dermatol       Date:  2011-05-17       Impact factor: 9.302

9.  Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa.

Authors:  R Thomi; D Yerly; N Yawalkar; D Simon; C Schlapbach; R E Hunger
Journal:  Br J Dermatol       Date:  2017-09-27       Impact factor: 9.302

10.  Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa.

Authors:  Claire Hotz; Michele Boniotto; Aurélie Guguin; Mathieu Surenaud; Francette Jean-Louis; Pascaline Tisserand; Nicolas Ortonne; Barbara Hersant; Romain Bosc; Florence Poli; Henri Bonnabau; Rodolphe Thiébaut; Véronique Godot; Pierre Wolkenstein; Hakim Hocini; Yves Lévy; Sophie Hüe
Journal:  J Invest Dermatol       Date:  2016-05-17       Impact factor: 8.551

View more
  13 in total

1.  Analysis of hidradenitis suppurativa-linked mutations in four genes and the effects of PSEN1-P242LfsX11 on cytokine and chemokine expression in macrophages.

Authors:  Airong Li; Yang Peng; Lauren M Taiclet; Rudolph E Tanzi
Journal:  Hum Mol Genet       Date:  2019-04-01       Impact factor: 6.150

Review 2.  Botulinum toxin type A for the management of hidradenitis suppurativa.

Authors:  Huanhuan Qu; Lin Gao
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 3.  The Skin and Gut Microbiome in Hidradenitis Suppurativa: Current Understanding and Future Considerations for Research and Treatment.

Authors:  Marisa E Luck; Joy Tao; Eden P Lake
Journal:  Am J Clin Dermatol       Date:  2022-09-18       Impact factor: 6.233

4.  Association of Vascular Endothelial Growth Factor Subtypes with Melanoma Patients' Characteristics and Survival: A Semantic Connectivity Map Analysis.

Authors:  Simone Cazzaniga; Christina Wiedmer; Živa Frangež; Maziar Shafighi; Helmut Beltraminelli; Benedikt Weber; Dagmar Simon; Luigi Naldi; Hans-Uwe Simon; Robert E Hunger; S Morteza Seyed Jafari
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

5.  Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors.

Authors:  Andreas Pinter; Georgios Kokolakis; Juergen Rech; Mona H C Biermann; Benjamin M Häberle; Jan Multmeier; Maximilian Reinhardt
Journal:  Dermatol Ther (Heidelb)       Date:  2020-06-04

Review 6.  An Integrated Approach to Unravel Hidradenitis Suppurativa Etiopathogenesis.

Authors:  Paola M Tricarico; Michele Boniotto; Giovanni Genovese; Christos C Zouboulis; Angelo V Marzano; Sergio Crovella
Journal:  Front Immunol       Date:  2019-04-25       Impact factor: 7.561

Review 7.  The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside.

Authors:  Taoming Liu; Sheng Li; Shuni Ying; Shunli Tang; Yuwei Ding; Yali Li; Jianjun Qiao; Hong Fang
Journal:  Front Immunol       Date:  2020-11-17       Impact factor: 7.561

Review 8.  Interleukin-17: Potential Target for Chronic Wounds.

Authors:  Yasmin Hadian; Michelle D Bagood; Sara E Dahle; Apra Sood; R Rivkah Isseroff
Journal:  Mediators Inflamm       Date:  2019-11-18       Impact factor: 4.711

Review 9.  Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm.

Authors:  S Morteza Seyed Jafari; Robert E Hunger; Christoph Schlapbach
Journal:  Front Med (Lausanne)       Date:  2020-03-04

10.  Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapy.

Authors:  Margaret M Lowe; Haley B Naik; Sean Clancy; Mariela Pauli; Kathleen M Smith; Yingtao Bi; Robert Dunstan; Johann E Gudjonsson; Maia Paul; Hobart Harris; Esther Kim; Uk Sok Shin; Richard Ahn; Wilson Liao; Scott L Hansen; Michael D Rosenblum
Journal:  JCI Insight       Date:  2020-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.